Bayer Healthcare LLC v. Apotex Inc.
1:16-cv-01221
Overview
Parties
Defendant
Teva Pharmaceutical Industries, Ltd. Operating Company
Represented By
0 Attorneys ListedBayer HealthCare Pharmaceuticals Inc. Operating Company
Represented By
0 Attorneys ListedTeva Pharmaceuticals USA, Inc. Operating Company
Represented By
0 Attorneys ListedCourt & Judges
Court
District Court, D. Delaware (ded)
Presiding Judge
Global Patent Family Cross-Litigation Radar
CasLoc 360Β° Radar 3 Family MembersMulti-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions
| Jurisdiction | Publication Number | Relationship | Official Record |
|---|---|---|---|
| πΊπΈ United States | Asserted | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US Continuation / Sibling | View Official Patent → | |
| π PCT International (WIPO) | PCT World Application | View Official Patent → |
Fustibal LLC v. Bayer HealthCare LLC
Patents Involved
There are 4 patents involved in this case.
| Patent Asset | Filing & Issue Date | Expiration & Term Status | External Links |
|---|---|---|---|
|
US7351834
Ο-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
Filed: 2000-01-12
Issued: 2008-04-01
|
Expired (Term Ended)
+898d PTA
Expires: 2022-06-28
|
|
|
US8637553
Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
|
Filed: 2004-07-22
Issued: 2014-01-28
|
Active (4.2 yrs remaining)
+2400d PTA
Expires: 2031-02-16
|
|
|
US8680124
Treatment of cancers with acquired resistance to kit inhibitors
|
Filed: 2008-01-18
Issued: 2014-03-25
|
Active (3.5 yrs remaining)
+866d PTA
Expires: 2030-06-02
|
|
|
US9458107
Process for the preparation of 4-{4-[({[4 chloro-3-(trifluoromethyl)-phenyl]amino}carbonyl)amino]-3-fluorphenoxy-N-ethylpyridie-carboxamide, its salts and monohydrate
|
Filed: 2014-04-15
Issued: 2016-10-04
|
Active (7.4 yrs remaining)
Expires: 2034-04-15
|
Patent Enforceability & Injunction Risk Assessment
Statutorily Barred β Patent expired. Under 35 U.S.C. Β§ 283, injunctive relief is barred.
High PTA (+898 days) / In re Cellect scrutiny applies.
Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).
Procedural Motions & Interlocutory Orders
Total Motions
4
Dispositive
0
Granted
0
Denied
0
Pending / Review
4
Motions by Category
Key Dispositive Motions & Rulings